Statins for primary cardiovascular prevention in the elderly

Journal of Geriatric Cardiology

Volumn 12, Issue 4, 2015, Pages 431-438

  Pedro Botet, Juan ^a   Climent, Elisenda ^a   Chillarón, Juan J ^a   Toro, Rocio ^b   Benaiges, David ^a   Flores Le Roux, Juana A ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF CÁDIZ   (Spain)

Author keywords

Cardiovascular disease; Dyslipidaemia; Elderly; Primary prevention; Statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE KIDNEY FAILURE; AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CATARACT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; DEMENTIA; DRUG SAFETY; GERIATRIC DISORDER; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRANSAMINASEMIA; ISCHEMIC HEART DISEASE; LIVER INJURY; META ANALYSIS (TOPIC); MORBIDITY; MUSCULOSKELETAL PAIN; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); UNSTABLE ANGINA PECTORIS;

EID: 84939520120     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.04.016     Document Type: Review

References (82)

1. Go AS, Mozaffarian D, Roger VL, et al; Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292
2. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-2934.
4. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. JAMA 2014; 312: 1136-1144.
5. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-1870.
6. Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations. Am J Geriatr Cardiol 2004; 13 (Suppl 1): S29-S33.
7. Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc 2009; 101: 705-710.
8. Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010; 4: 483-490.
9. Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults. A scientific statement from the American Heart Association. Circulation 2013; 128: 2422-2446.
10. Zannad F, Dallongeville J, Macfadyen RJ, et al. Prevention of cardiovascular disease guided by total risk estimations e challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. Eur J Prev Cardiol 2012; 19: 1454-1464.
11. Reiner Z. How to improve cardiovascular diseases prevention in Europe? Nutr Metab Cardiovasc Dis 2009; 19: 451-454.
12. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
13. Abbott RD, Garrison RJ, Wilson PW, et al. Joint distribution of lipoprotein cholesterol classes. The Framingham study. Arteriosclerosis 1983; 3: 260-272.
14. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res. 1994; 35: 779-792.
15. Gobal FA, Mehta JL. Management of dyslipidemia in the elderly population. Ther Adv Cardiovasc Dis 2010; 4: 375-383.
16. Ericsson S, Eriksson M, Vitols S, et al. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest 1991; 87: 591-596.
17. Liu H, Li J. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev 2015; 19: 43-52.
18. Lemieux I, Pascot A, Tchernof A, et al. Visceral adipose tissue and low-density lipoprotein particle size in middle-aged versus young men. Metabolism 1999; 48: 1322-1327.
19. Walter M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1244-1250.
20. Kronmal RA, Cain KC, Ye Z, et al. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993; 153: 1065-1073.
21. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119-1123.
22. Schatz IJ, Masaki K, Yano K, et al. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358: 351-355.
23. Foody JM, Rathore SS, Galusha D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 2006; 54: 421-430.
24. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63: 747-762.
25. Tilvis RS, Valvanne JN, Strandberg TE, et al. Prognostic significance of serum cholesterol, lathosterol, and sitosterol in old age; a 17-year population study. Ann Med 2011; 43: 292-301.
26. Fontana L, Addante F, Copetti M, et al. Identification of a metabolic signature for multidimensional impairment and mortality risk in hospitalized older patients. Aging Cell 2013; 12: 459-466.
27. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126: 753-760.
28. Petretta M, Costanzo P, Perrone-Filardi P, et al. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010; 138: 25-31.
29. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
30. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59: 572-582.
31. Mosca L. Sex, statins, and statistics. Lancet 2015; 385: 1368-1369.
32. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
33. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; 1: CD004816.
34. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
35. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
36. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
37. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
38. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29: 2378-2384.
39. Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging 2011; 28: 681-692.
40. Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395-1400.
41. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
42. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010; 152: 488-496.
43. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009; 338: b2376.
44. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2013; 62: 2090-2099.
45. Sigurdsson AF. Benefits of statins in healthy elderly subjects: what is the number needed to treat? J Am Coll Cardiol 2014; 63: 2302.
46. Savarese G, Perrone-Filardi P. Benefits of statins in healthy elderly subjects: what is the number needed to treat? J Am Coll Cardiol 2014; 63: 2303.
47. STAREE Study Investigators. A clinical trial of statin therapy for reducing events in the elderly (STAREE), 2014. Clinical-Trials.gov Website. http://clinicaltrials.gov/show/NCT02099123. (Accessed Jan 21, 2015).
48. Phan BA, Bittner V. Lipid-lowering therapy in patients 75 years and older: clinical priority or superfluous therapy? Prog Cardiovasc Dis 2014; 57: 187-196.
49. Schwartz JB. Primary prevention: do the very elderly require a different approach? Trends Cardiovasc Med 2015; 25: 228-239.
50. Expert Dyslipidemia Panel, Grundy SM. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 2013; 7: 561-565.
51. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29: 151-167.
52. Yan YL, Qiu B, Hu LJ, et al. Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2013; 69: 2001-2009.
53. Cohen JD, Brinton EA, Ito MK, et al. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6: 208-215.
54. Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013; 159: 688-697.
55. Desai C, Martin S, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014; 349: g3743.
56. Padala KP, Padala PR, McNeilly DP, et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012; 10: 296-302.
57. US Food and Drug Administration, Clarke PE. Cholesterol lowering drugs get labeling changes, 2014. U.S. Food and Drug Administration Website. http://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm290856.htm. (Accessed Jan 19, 2015).
58. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013; 88: 1213-1221.
59. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
60. Ridker PM, Pradhan A, Mac Fadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-571.
61. Pharmacovigilance Working Party (PhVWP): December 2011 plenary meeting, 2012. European Medicines Agency Website. http://www.ema.europa.eu/docs/en-GB/document-library/Re port/2012/01/WC500120115.pdf. (Accessed Jan 14, 2015).
62. Water DD, Ho JE, Demicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535-1545.
63. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-2564.
64. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patient treated with statins: population based study. BMJ. 2013; 346: f2610.
65. Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol 2013; 75: 1118-1124.
66. Dormuth CR, Filion KB, Paterson JM, et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014; 348: g3244.
67. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for the clinical practice. Atheroscler Suppl 2014; 15: 1-15.
68. Argo CK, Loria P, Caldwell SH, et al. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 2008; 48: 662-669.
69. Oni ET, Sinha P, KarimA, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res 2014; 45: 52-57.
70. Younoszai Z, Li Z, Stepanova M, et al. Statin use is not associated with liver related mortality. Ann Hepatol 2013-2014; 13: 84-90.
71. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs, 2012. U.S. Food and Drug Administration Website. http://www.fda.gov/drugs/drugsafety/ucm293101.htm. (Accessed Jan 20, 2015).
72. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013; 346: f880.
73. Bangalore S, Fayyad R, Hovingh GK, et al. Statin and the risk of renal-related serious adverse events: analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol 2014; 113: 2018-2020.
74. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340: c2197.
75. Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 2013; 131: 1427-1434.
76. Kostis JB, Dobrzynski JM. Prevention of cataracts by statins: a meta-analysis. J Cardiovasc Pharmacol Ther 2014; 19: 191-200.
77. Wieseler B, Wolfram N, McGauran N, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med. 2013; 10: e1001526.
78. Catalá-López F, Sanfélix-Gimeno G, Ridao M, et al. When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins. PLoS One 2013; 8: e69462.
79. Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J 2012; 105: 437-445.
80. Wilmot KA, Khan A, Krishnan S, et al. Statins in the elderly: a patient-focused approach. Clin Cardiol 2015; 38: 56-61.
81. Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2008; 2: 453-463.
82. Fried TR, Tinetti ME, Towle V, et al. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011; 171: 923-928.